Thesis
Livongo (LVGO) is a fast-growing healthcare technology company focused on the treatment of common, treatable diseases like diabetes. The company sells its disease management solution to employers and health plans on a subscription basis.
Q3 revenue grew at a torrid 148% and the company raised revenue guidance going into Q4. However, the company doesn't expect to be profitable for the foreseeable future as it invests to expand in a $12 billion market, of which it has approximately a 1% share.
The company is attractive due to its strong growth, the large addressable